Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study
- Authors
- Hong, Soon Jun; Sung, Ki-Chul; Lim, Sang-Wook; Kim, Seok-Yeon; Kim, Weon; Shin, Jinho; Park, Sungha; Kim, Hae-Young; Rhee, Moo-Yong
- Issue Date
- 2020
- Publisher
- DOVE MEDICAL PRESS LTD
- Keywords
- hypertension; blood pressure; combination therapy; low-dose; amlodipine; losartan; chlorthalidone
- Citation
- DRUG DESIGN DEVELOPMENT AND THERAPY, v.14, pp.5735 - 5746
- Indexed
- SCIE
SCOPUS
- Journal Title
- DRUG DESIGN DEVELOPMENT AND THERAPY
- Volume
- 14
- Start Page
- 5735
- End Page
- 5746
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/59062
- DOI
- 10.2147/DDDT.S286586
- ISSN
- 1177-8881
- Abstract
- Purpose: We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple antihypertensive combination therapies in patients with mild-to-moderate hypertension. Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to week 8. Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were -17.2, -19.5, -14.9, -18.5, -11.3 and -9.9 mmHg, respectively. The BP control and response rates were significantly higher in the half-dose, third-dose, and quarter-dose combination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in study drug-related adverse events, ankle circumference increased significantly in the amlodipine group compared to those in the combination treatment groups. The quarter-dose combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction and BP response rates. The SBP reduction and BP response rate in the third-dose and half-dose combination groups were not significantly different from those in the amlodipine 10 mg group but superior to those in the losartan 100 mg group. Conclusion: Low-dose triple combination therapies could be effective as antihypertensive therapies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
- College of Health Sciences > Division of Health Policy and Management > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/59062)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.